mRNA Melanoma Vaccine Cuts Risk of Recurrence or Death, Leaked Trial Data Show

(MedPage Today) -- Adjuvant treatment with the mRNA-based cancer vaccine intismeran autogene plus pembrolizumab (Keytruda) significantly improved recurrence-free survival (RFS) in patients with resected stage IIB-IV melanoma, the phase III INTerpath...

Read it at MedPage Today ↗

← Front page